Bradykinesia is a medical condition characterized by slow movement, often linked to Parkinson’s disease. It is different from hypokinesia, which focuses on the initiation of movement. Antipsychotic drugs can also cause bradykinesia, but it can be treated with L-DOPA.
Bradykinesia is a medical condition characterized by impaired mobility in people who have been diagnosed with the condition. The name of the condition is literally translated as meaning “slow movement”. Bradykinesia is sometimes confused with hypokinesia, but it’s actually a different affliction.
A person diagnosed with bradykinesia has usually already been identified as having one of several diseases. Often, the condition is a symptom linked to Parkinson’s disease. Because of the impact of this disease on basal ganglia function, the patient may have great difficulty completing a movement once attempted.
The process of bradykinesia is similar to that of hypokinesia but it actually addresses a completely different condition. While all forms of Chinese have to do with movement, hypokinesia focuses on the difficult initiation of movement. In contrast, bradykinesia has to do with the speed of movement once movement has begun. It is possible for an individual patient to experience both conditions, finding difficulty initiating the movement and thus also having difficulty following the logical conclusion of the movement.
In addition to being closely associated with Parkinson’s, bradykinesia can sometimes occur due to the use of antipsychotic drugs. Due to the calming nature of many antipsychotic drugs, the patient may enter a calm state in which movement is markedly slowed. Qualified physicians may be able to adjust dosages so the medications can achieve the desired calm state without creating an unusually large amount of difficulty with movement. It is important to note that antipsychotic drugs do not cause bradykinesia in all patients.
A fairly common form of treatment for bradykinesia is the use of the drug L-DOPA. Usually administered orally, this drug is a precursor that will convert to dopamine once the pill dissolves in the body. Various drugs couple L-DOPA with some type of inhibitory agent that doesn’t allow for the conversion until the drug reaches the brain. This allows for maximum effect in countering a state of bradykinesia and can help improve the patient’s response to all types of kinesthetic stimuli.
Protect your devices with Threat Protection by NordVPN
